ZOSTAVAX™ (concomitant)

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Herpes Zoster

View Full Landscape

Drug Information

Target Indication

Herpes Zoster

Clinical Trial

NCT00231816

Last updated: 12/17/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/19/2006

Zostavax

Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. Zostavax is indicated for immunisation of individuals 50 years of age or older.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis

Simvastatin 20 mg dailyPhase 3

Cardiovascular Disease

EpinephrinePhase 3

Malignant Neoplasms of Male Genital Organs

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3

HPV Positive Oropharyngeal Squamous Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts